The Atrial Fibrillation Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Atrial Fibrillation Market:
https://www.thebusinessresearchcompany.com/report/atrial-fibrillation-global-market-report
According to The Business Research Company’s Atrial Fibrillation Global Market Report 2024, The atrial fibrillation market size has grown rapidly in recent years. It will grow from $12.02 billion in 2023 to $13.47 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing awareness and screening programs, technological innovations in treatment, increasing healthcare expenditure, clinical research and drug development, genetic predisposition..
The atrial fibrillation market size is expected to see rapid growth in the next few years. It will grow to $21.66 billion in 2028 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to focus on stroke prevention, patient and physician education programs, global initiatives for cardiovascular health, increasing electrophysiology procedures, customization of treatment plans, government initiatives for cardiovascular disease prevention.. Major trends in the forecast period include advancements in diagnostic technologies, rise in the incidence of atrial fibrillation, advancements in catheter ablation techniques, emergence of novel oral anticoagulants (noacs), integration of wearable technologies for monitoring, expanding role of telemedicine in af management, advancements in implantable devices..
The increase in the geriatric population is expected to drive the atrial fibrillation market forward. The geriatric population refers to adults 65 and older who are more likely to fall due to various factors, such as postural hypotension and balance or gait problems. Age factor and conduction disturbances are present on the surface electrocardiogram before AF onset in most geriatric patients. For instance, in October 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations responsible for international public health, six people in the world will be aged 60 years or older by 2030. At this point, there will be 1.4 billion people, up from 1 billion in 2020, who are 60 years of age or older. The number of individuals 60 and older in the world will double (to 2.1 billion) by the year 2050. Between 2020 and 2050, there will be 426 million more people who are 80 years of age or older than there are today. Therefore, the growing geriatric population is driving the growth of the atrial fibrillation market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=8007&type=smp
The atrial fibrillation market covered in this report is segmented –
1) By Type: Surgical, Non-Surgical
2) By Technology: Radiofrequency, Laser, Cryotherapy, Other Technologies
3) By Treatment Type: Pharmacological Treatment, Non-pharmacological Treatment, Maze Surgery, Electric Cardioversion
4) By End User: Hospitals, Electrophysiology Labs, Ambulatory Surgical Centers
Major companies in the atrial fibrillation market are launching innovative products and solutions such as patient-centric clinical decision support tools to strengthen their position in the market. Clinical decision support tools (CDST) are software or electronic systems designed to assist healthcare professionals in making informed and timely decisions about patient care. These tools are developed to integrate relevant clinical information from various sources. For instance, in August 2023, GE HealthCare, a US-based multinational medical technology company launched the CardioVisio, a patient-centered clinical decision support tool to help doctors drive evidence-based clinical decision support guided by current atrial fibrillation guidelines and visualize longitudinal data from various data sources relevant for illness progression. CardioVisio for atrial fibrillation, can assist cardiologists with in streamlining clinician image interpretation and to provide a view of the history of the patient’s heart as well as their healthcare journey, including previous diagnoses, prescribed medications, interventions, and comorbidities.
The atrial fibrillation market report table of contents includes:
1. Executive Summary
- Atrial Fibrillation Market Characteristics
- Atrial Fibrillation Market Trends And Strategies
- Atrial Fibrillation Market – Macro Economic Scenario
- Global Atrial Fibrillation Market Size and Growth
.
31. Global Atrial Fibrillation Market Competitive Benchmarking - Global Atrial Fibrillation Market Competitive Dashboard
- Key Mergers And Acquisitions In The Atrial Fibrillation Market
- Atrial Fibrillation Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
